Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Jul 11, 2019 2:02pm

58 Views

Post# 29909540

RE:RE:RE:Luc: HIV NASH 8-10x current Egrifta market

Maybe someone can help be to understand how Trogarzo sales and Egrifta are now equivalent.

So, I believe Trogarzo sales was 7 million last quarter, which leaves 8.6 milliona for Egrifta. If Trogarzo continues its early sales trend to improve by 20% then sales for Q3 would be 8.4 million, still 200,000 shy of Egrift sales. So how can Luc say that sales were equivalent as of June?

Bullboard Posts

Breakout: An antimicrobial biotechnology quietly building success